Vertex BioPharm Consulting

03/04/2026

At Vertex BioPharm Consulting, we ensure cGMP facility built out or retrofit with your requirements and cGMP compliance. We consult in various stage of your plan such as concept, design and engineering, commissioning and validation, documentation and automation for cGMP facility. Contact us at info@vertexbiopharm.com for additional information.
https://vertexbiopharm.com

03/04/2026

03/04/2026

Vertex Biopharm Consulting is proud to take part of Asian Venture Capital Journal (AVCJ) Private Equity Forum Australia & New Zealand 2026
The big issue: Can continuation vehicles be a win-win-win?
Continuation vehicles (CVs) have proliferated in private equity, helping managers generate liquidity and propelling GP-led secondaries volume to record highs. This is a US-led phenomenon, but it’s driving a global debate. Investors are scrutinising GP motivations – focusing on asset selection, transaction timing, and economic incentives – as well as process integrity, specifically approaches to valuation, disclosure, and potential conflicts of interest. In the background, pools of capital targeting secondaries are growing in number and in volume.
Are CVs a near-term liquidity fix or a long-term structural trend?
Is it appropriate for a broken sale process to shift to a CV process?
What potential red flags should LPs look out for when asked to exit or roll?
Can CVs be used to generate co-investment and get access to top-tier GPs?

03/04/2026

Review: The development of CAR T cells for patients with CNS malignancies
Chimeric antigen receptor (CAR) T cells have become standard-of-care therapies for patients with certain relapsed and/or refractory haematological malignancies over the past decade. However, this approach remains largely ineffective in patients with solid tumours, in part owing to limited CAR T cell persistence, the immunosuppressive tumour microenvironment of many solid tumours and limited trafficking of CAR T cells into tumours. Central nervous system (CNS) tumours, many of which are associated with a poor prognosis and require new treatment approaches, present additional challenges such as the presence of the blood–brain barrier as well as concerns over treatment-related neurotoxicities.

Presented by ‪‪‪Vertex BioPharmConsulting‬ https://vertexbiopharm.comComprehensive solutions for1. Patent/Corporate Legal2. CMC Strategy3. Manufacturing & A...

03/03/2026

Corporate Legal, Merges & Acquisitions, Due Diligence, and Intellectual Property
Vertex BioPharm Consulting, with experienced scientist and attorney, provides comprehensive solutions for corporate legals such as entity formation and governance, contract strategy, Merges and Acquisition, Due Diligence, intellectual property, and global patent portfolio strategies. Contact us at info@vertexbiopharm.com for consultation. Our teams are looking forward to supporting your success and compliance.
https://vertexbiopharm.com/
https://youtu.be/FBUGHvoJjp0

03/03/2026

Claudin proteins as emerging therapeutic targets for solid tumours
Claudins (CLDNs) are transmembrane proteins that contribute to the epithelial cell polarity and integrity of tight junctions in healthy tissues. CLDNs are frequently overexpressed across different solid tumours, and expression correlates with tumour subtype, grade and prognosis. Dysregulated CLDN expression modulates oncogenic signalling and contributes to tumour proliferation, epithelial–mesenchymal transition, stemness, fibrosis, immune modulation and therapeutic resistance. Owing to their frequent overexpression and functional role in cancer biology, CLDNs have emerged as attractive therapeutic targets. Their surface expression can be exploited to guide therapies into tumours.

Presented by ‪‪‪Vertex BioPharmConsulting‬ https://vertexbiopharm.comComprehensive solutions for1. Patent/Corporate Legal2. CMC Strategy3. Manufacturing & A...

03/02/2026

VBC provides comprehensive solutions for
Process Development, Manufacturing for Drug Substances and Drug Process, PPQ, Method Development
https://www.youtube.com/watch?v=8iyedG3RE30
https://vertexbiopharm.com/

Presented by ‪‪‪‪‬ https://vertexbiopharm.comComprehensive solutions for1. Patent/Corporate Legal2. CMC Strategy3. Manufacturing & ...

03/02/2026

Vertex BioPharm Consulting (VBC) is proud of having the leading Ex-FDA experts in non-clinical and clinical reviews for IND-enabling, NDA and BLA filings. VBC will ensure your regulatory readiness in any stages such as setting meeting with FDA, Pre-IND, IND-enabling, NDA or BLA filing.

https://youtu.be/KVNnL8QDzQ8
https://vertexbiopharm.com/

Presented by ‪‪‪‪‬ https://vertexbiopharm.comComprehensive solutions for1. Patent/Corporate Legal2. CMC Strategy3. Manufacturing & ...

03/01/2026

A small-scale model for cell culture perfusion of monoclonal antibody in CHO cells

Presented by ‪‪‪ https://vertexbiopharm.comComprehensive solutions for1. Patent/Corporate Legal2. CMC Strategy3. Manufacturing & Au...